AstraZeneca’s New Oral GLP-1 Medication Shows Promise for Weight Loss and Blood Sugar Control
AstraZeneca has recently announced encouraging results from a phase 2b clinical trial of its new oral medication, elecoglipron, which targets type 2 diabetes. The trial revealed that participants experienced an average weight loss of 10.5% over the course of 26 weeks, alongside significant reductions in blood sugar levels. The findings were presented at the American…
